--- title: "Mechanism of response to FHD-286 plus decitabine in advanced myeloid malignancies" id: "medrxiv-15-mechanism-of-response-to-fhd-286-and-decitabine-combination-in-patients-with" canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-15-mechanism-of-response-to-fhd-286-and-decitabine-combination-in-patients-with" content_type: "clinical_feed_article" specialty: "Oncology" source_name: "medRxiv (Clinical Preprints)" source_url: "https://www.medrxiv.org/content/10.64898/2026.07.17.26358055v1?rss=1" published_at: "2026-07-20T12:00:00.000Z" evidence_level: "Verified Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Mechanism of response to FHD-286 plus decitabine in advanced myeloid malignancies ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-15-mechanism-of-response-to-fhd-286-and-decitabine-combination-in-patients-with - **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md) - **Primary Source:** medRxiv (Clinical Preprints) - **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.17.26358055v1?rss=1) - **Published At:** 2026-07-20T12:00:00.000Z - **Evidence Rating:** Verified Feed ## Executive GIST (TL;DR) - This preprint reports mechanistic analyses from a phase 1 trial combining the dual **SMARCA4/2** inhibitor **FHD-286** with **decitabine (DAC)** in patients with advanced myeloid malignancies. The combination was tolerated and produced an objective response rate of 12.8% (6/47), whereas no responses were observed with FHD-286 monotherapy. - Investigators applied high-dimensional flow cytometry and single-cell genomic profiling to longitudinal bone marrow samples from responders and nonresponders to probe cellular and transcriptional changes associated with treatment. - FHD-286 monotherapy primarily drove **myeloid differentiation** phenotypes. In contrast, responders to the FHD-286+DAC combination demonstrated diverse differentiation trajectories that included both myeloid and **erythroid** lineages. - The combination potentiated the transcriptional effects of DAC, promoting full differentiation of tumor clones out of the immunophenotypic and transcriptional blast compartment rather than merely partial lineage shifts. - Responders displayed a baseline transcriptional signature resembling **CEBPA**-mutant acute myeloid leukemia and showed further downregulation of **CEBPA** upon treatment, linking CEBPA-related programs to sensitivity. - Findings support tumor cell differentiation as an on-target mechanism of response to pharmacologic SMARCA4/2 inhibition and provide rationale to evaluate FHD-286+DAC in molecularly defined patient subsets. - This work is reported as a clinical preprint and has not undergone peer review; detailed methods, full datasets, and longer-term clinical outcomes beyond the phase 1 report were not fully reported in the preprint. - Trial registration: NCT04891757. The study was supported by Foghorn Therapeutics and includes multiple declared competing interests and institutional approvals from participating centers. ## Clinical Analysis & Structured Key Points Skip to main content HOMESUBMITFAQBLOGALERTS / RSSRESOURCESABOUT Search for this keyword Advanced Search Follow this preprint Mechanism of response to FHD-286 and decitabine combination in patients with advanced myeloid malignancies Michael P Collins, David L Lahr, Salih Topal, View ORCID Profile Alexis Khalil, Denice Hickman, Nicholas Spidale, Nikhil Pandit, View ORCID Profile Sarah Reilly, Kelly Lyons, Kim Horrigan, Tina Zhao, Joelle Batonga, Mia Bosinger, View ORCID Profile Katie D'Aco, View ORCID Profile Brian Ball, View ORCID Profile Ashwin Kishtagari, View ORCID Profile Courtney D DiNardo, Eytan M Stein, View ORCID Profile Alfonso Quintás-Cardama, View ORCID Profile Gromoslaw A Smolen doi: https://doi.org/10.64898/2026.07.17.26358055 This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. AbstractInfo/HistoryMetrics Preview PDF Abstract Impaired cellular differentiation is a defining characteristic of myeloid malignancies and remains a major therapeutic challenge. The BRG1/Brahma-associated factor (BAF) chromatin remodeling complex, through the ATPases SMARCA4 and SMARCA2, maintains the stemness of leukemic blasts and thus represents a promising target for novel differentiation-based therapies. In a phase 1 study in advanced myeloid malignancies, the first-in-class dual SMARCA4/2 inhibitor FHD-286 combined with decitabine (DAC) was tolerated and produced an objective response rate of 12.8% (6/47) compared with no responses with FHD-286 monotherapy. To understand the basis of this activity, we integrated high-dimensional flow cytometry and single-cell genomic analyses of longitudinal bone marrow samples from responders and nonresponders. While FHD-286 monotherapy was predominantly associated with myeloid differentiation, responders to FHD-286+DAC combination therapy exhibited a range of myeloid and erythroid differentiation trajectories. FHD-286 potentiated the transcriptional impact of DAC, driving tumor clones to fully differentiate out of the immunophenotypically and transcriptionally defined blast compartment. Responders had a baseline transcriptional profile similar to that of CEBPA-mutant acute myeloid leukemia and showed further downregulation of CEBPA upon treatment. These findings reinforce tumor cell differentiation as a mechanism of response to pharmacologic SMARCA4/2 inhibition and support further evaluation of FHD-286+DAC in molecularly defined patient subsets. Competing Interest Statement AK declares consulting relationships with Sobi, Geron Corporation, MorphoSys AG, Rigel Pharmaceuticals, Servier Pharmaceuticals, Syndax Pharmaceuticals, Blueprint Medicines, Ascentage Pharma, Takeda Oncology, Cogent Biosciences, and Novartis. The author serves as co-host of Blood Cancer Talks podcast and has received honoraria and consulting fees from the aforementioned companies within the past 36 months. APK, DH, GAS, and NP declare employment by and stock options in Foghorn Therapeutics Inc. AQ-C, NS, and ST declare employment by Foghorn Therapeutics Inc. CDD declares consultancy for AbbVie, AstraZeneca, Astellas, BeOne, BMS, Kura, Rigel, Servier, Solu, and Systimmune. CDD is supported by the LLS Scholar in Clinical Research Award. DLL declares employment by and stock in Foghorn Therapeutics Inc., inventor on patent for use of FHD-286 in treating cancer: US Patent # 12383555, Methods of treating cancers. EMS declares institutional research support from and consulting for Foghorn Therapeutics Inc. JB declares employment by Certara. KD declares employment by Diamond Age Data Science. KH and KL declare former employment by Foghorn Therapeutics Inc. MB declares employment by Diamond Age Data Science and the Worcester Polytechnic Institute. MPC declares employment by and stock options in Foghorn Therapeutics Inc. and patent applications WO2025080767A1 and WO2026085172A1. SAR declares employment by Akebia Therapeutics, former employment by Foghorn Therapeutics Inc., and stock in Adaptimmune Therapeutics and Foghorn Therapeutics Inc. The remaining authors declare that they have no competing interests. Clinical Trial NCT04891757 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The MD Anderson Cancer Center Office of Human Subject Protection, Memorial Sloan Kettering Cancer Center IRB/Privacy Board, Dana-Farber Cancer Institute Office for Human Research Studies, Vanderbilt University Medical Center IRB, and City of Hope National Medical Center Office for Human Research Subjects Protection gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes FUNDER INFORMATION DECLARED Foghorn Therapeutics (United States), https://ror.org/05j5rbv93 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. Donate to openRxiv Back to top Previous Next Posted July 20, 2026. Download PDF Print/Save Options Author Declarations Supplementary Material Data/Code Email Share Citation Tools Get QR code Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos Subject Areas All Articles Addiction Medicine Allergy and Immunology Anesthesia Cardiovascular Medicine Dentistry and Oral Medicine Dermatology Emergency Medicine Endocrinology (including Diabetes Mellitus and Metabolic Disease) Epidemiology Forensic Medicine Gastroenterology Genetic and Genomic Medicine Geriatric Medicine Health Economics Health Informatics Health Policy Health Systems and Quality Improvement Hematology HIV/AIDS Infectious Diseases (except HIV/AIDS) Intensive Care and Critical Care Medicine Medical Education Medical Ethics Nephrology Neurology Nursing Nutrition Obstetrics and Gynecology Occupational and Environmental Health Oncology Ophthalmology Orthopedics Otolaryngology Pain Medicine Palliative Medicine Pathology Pediatrics Pharmacology and Therapeutics Primary Care Research Psychiatry and Clinical Psychology Public and Global Health Radiology and Imaging Rehabilitation Medicine and Physical Therapy Respiratory Medicine Rheumatology Sexual and Reproductive Health Sports Medicine Surgery Toxicology Transplantation Urology Evaluation/discussion of this paper x 0 0 0 0 0 0 We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. Continue Find out more ## Related Clinical Research - [UM171‑Expanded Cord Blood Transplantation for High‑Risk Acute Leukemia and MDS in Adults](https://medichelpline.com/clinical-feed/medrxiv-18-um171-expanded-cord-blood-transplantation-in-adults-with-high-and-very-high.md) - [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md) - [Higher dietary antioxidants linked to lower odds of cervical cancer in NHANES analysis](https://medichelpline.com/clinical-feed/medical-news-today-1-study-finds-link-between-antioxidant-rich-diets-and-lower-cervical-cancer-odds.md) - [How pre-vaccination immunity heterogeneity drives variability in vaccine effectiveness estimates](https://medichelpline.com/clinical-feed/medrxiv-5-heterogeneity-in-pre-vaccination-population-immunity-can-contribute-to.md) - [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md) ## Navigation - [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.